Imara M&A

ELVN-001 Clinical Focus and Target Product Profile Our Opportunity ● Target Product Profile Drive Deeper Responses ● Improve Tolerability ● Enhance Safety & Convenience High selectivity vs. clinically relevant off-targets Efficacy: MMR (& MR4.5) greater than approved TKIs driven by an enhanced therapeutic window Tolerability: fewer dose reductions & discontinuations Safety: No black box warnings; no edema, effusions, or rash • No restrictions with concomitant medications Activity against native BCR-ABL and T3151 mutation (& known asciminib resistant mutations) CCYR Complete cytogenetic response. CP-CML = Chronic phase CML. H2H = Head-to-head. LoT = Line of therapy. MMR = Major molecular response. MR4.5 = Deep molecular response. TKI = Tyrosine kinase inhibitors Dose Escalation in 3L+ and Expansion Progressed/Intolerant CP-CML Explore early LoT & combinations Seek to demonstrate improved efficacy (CCYR, MMR, MR4.5) and tolerability ● ● ● 4L+ and T3151 mutation ● Single-arm study; precedent for approval in last line based on CCYR/MMR by 12m T3151 mutation in ponatinib or asciminib progressed/intolerant/ineligible Early Line H2H vs Physician's Choice Superiority based on 12m MMR in CP-CML • Fewer dose reductions/discontinuations vs. approved agents ● 25

View entire presentation